Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare

6,560 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Strong Buy

17 Buy

5 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$519.69

▲(14.30% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $519.69 with a high forecast of $625.00 and a low forecast of $414.00. The average price target represents a 14.30% change from the last price of $454.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","513":"$513","626":"$626","456.5":"$456.5","569.5":"$569.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$625.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":519.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$519.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$414.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,456.5,513,569.5,626],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,453.36,466.56307692307695,479.7661538461539,492.96923076923076,506.1723076923077,519.3753846153846,532.5784615384615,545.7815384615385,558.9846153846154,572.1876923076923,585.3907692307693,598.5938461538461,611.7969230769231,{"y":625,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,453.36,458.4623076923077,463.5646153846154,468.6669230769231,473.7692307692308,478.8715384615385,483.9738461538462,489.0761538461539,494.1784615384616,499.2807692307693,504.38307692307694,509.48538461538465,514.5876923076924,{"y":519.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,453.36,450.3323076923077,447.3046153846154,444.2769230769231,441.2492307692308,438.22153846153844,435.19384615384615,432.16615384615386,429.13846153846157,426.1107692307692,423.08307692307693,420.05538461538464,417.0276923076923,{"y":414,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$625.00

Average Price Target$519.69

Lowest Price Target$414.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salveen Richter

Goldman Sachs

$625

Buy

37.46%

Upside

Reiterated

01/13/26

Goldman Sachs Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

We continue to rate Vertex Outperform and view the company as a core mid- to large-cap growth story in the biotech space.

Phil Nadeau

TD Cowen

$525

Buy

15.47%

Upside

Reiterated

01/12/26

TD Cowen Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

William Pickering

Bernstein

Buy

―

Upgraded

01/12/26

Vertex Pharmaceuticals upgraded to Outperform from Market Perform at BernsteinVertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein

Tazeen Ahmad

Bank of America Securities

$571

Buy

25.59%

Upside

Reiterated

01/12/26

We reiterate VRTX as one of our top 2026 picks and maintain our Buy with $571 PO.

Evan Seigerman

BMO Capital

$530

Buy

16.57%

Upside

Reiterated

01/11/26

Carter Gould

Cantor Fitzgerald

$485

Buy

6.67%

Upside

Reiterated

01/11/26

Brian Abrahams

RBC Capital

$415→$455

Hold

0.07%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and CareDx (NASDAQ: CDNA)

Michael Yee

UBS

$546→$535

Buy

17.67%

Upside

Reiterated

01/07/26

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Andy Chen

Wolfe Research

$548

Buy

20.53%

Upside

Upgraded

01/06/26

Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe ResearchVertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research

Geoff Meacham

Citi

$575

Buy

26.47%

Upside

Reiterated

01/05/26

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

David Risinger

Leerink Partners

$456→$525

Buy

15.47%

Upside

Reiterated

12/29/25

Vertex Pharmaceuticals price target raised to $525 from $456 at LeerinkVertex Pharmaceuticals price target raised to $525 from $456 at Leerink

Louise Chen

Scotiabank

$495

Buy

8.87%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

$460→$515

Buy

13.27%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

$516→$564

Buy

24.05%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salveen Richter

Goldman Sachs

$625

Buy

37.46%

Upside

Reiterated

01/13/26

Goldman Sachs Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

We continue to rate Vertex Outperform and view the company as a core mid- to large-cap growth story in the biotech space.

Phil Nadeau

TD Cowen

$525

Buy

15.47%

Upside

Reiterated

01/12/26

TD Cowen Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

William Pickering

Bernstein

Buy

―

Upgraded

01/12/26

Vertex Pharmaceuticals upgraded to Outperform from Market Perform at BernsteinVertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein

Tazeen Ahmad

Bank of America Securities

$571

Buy

25.59%

Upside

Reiterated

01/12/26

We reiterate VRTX as one of our top 2026 picks and maintain our Buy with $571 PO.

Evan Seigerman

BMO Capital

$530

Buy

16.57%

Upside

Reiterated

01/11/26

Carter Gould

Cantor Fitzgerald

$485

Buy

6.67%

Upside

Reiterated

01/11/26

Brian Abrahams

RBC Capital

$415→$455

Hold

0.07%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and CareDx (NASDAQ: CDNA)

Michael Yee

UBS

$546→$535

Buy

17.67%

Upside

Reiterated

01/07/26

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Andy Chen

Wolfe Research

$548

Buy

20.53%

Upside

Upgraded

01/06/26

Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe ResearchVertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research

Geoff Meacham

Citi

$575

Buy

26.47%

Upside

Reiterated

01/05/26

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

David Risinger

Leerink Partners

$456→$525

Buy

15.47%

Upside

Reiterated

12/29/25

Vertex Pharmaceuticals price target raised to $525 from $456 at LeerinkVertex Pharmaceuticals price target raised to $525 from $456 at Leerink

Louise Chen

Scotiabank

$495

Buy

8.87%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

$460→$515

Buy

13.27%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

$516→$564

Buy

24.05%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months

xxx

Success Rate

21/29 ratings generated profit

Average Return

+7.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +7.04% per trade.

1 Year

Geoff MeachamCiti

Success Rate

28/37 ratings generated profit

Average Return

+13.34%

reiterated a buy rating 10 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 75.68% of your transactions generating a profit, with an average return of +13.34% per trade.

2 Years

xxx

Success Rate

33/37 ratings generated profit

Average Return

+18.59%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.19% of your transactions generating a profit, with an average return of +18.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 38 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 519.69.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $5.08 with a range of $4.46 to $5.69. The previous quarter’s EPS was $4.80. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.18B with a range of $3.10B to $3.35B. The previous quarter’s sales results were $3.12B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 519.69.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 14.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s price target?

The average price target for Vertex Pharmaceuticals is 519.69. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $625.00 ,the lowest forecast is $414.00. The average price target represents 14.30% Increase from the current price of $454.67.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Detailed List of Analyst Forecasts